PATENT CLAIM ANALYSIS

Application Number: 16113150
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["536", "024500"]

Abstract:
The present invention provides an anti-influenza virus agent that targets biomolecules of host cells including human cells and a method of screening a candidate molecule for the anti-influenza virus agent. That is, the present invention is an anti-influenza virus agent that has an effect of suppressing expression or a function of a gene that encodes a protein having an effect of suppressing incorporation of an influenza virus vRNA or an NP protein into influenza virus-like particles in host cells and the gene is at least one selected from the group including JAK1 gene and the like.

Claim (Index 3):
The influenza treatment method according to  claim 1 ,\n wherein the anti-influenza virus agent is at least one selected from the group consisting of Ruxolitinib, Tofacitinib, Tofacitinib (CP-690550) Citrate, Tyrphostin B42 (AG-490), Baricitinib (LY3009104, INCB028050), AT9283, Momelotinib, CEP33779, NVP-BSK805, ZM39923, Filgotinib, JANEX-1, NVP-BSK805, SB1317, and WP1130.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 96.0
- Lexical Diversity: 1.83333
- Patent Class: 536.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13387293', '11832875', '11481411', '10700239', '15511988']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.665349185614748
- 35 USC 102 Novelty (BERT): 0.4969090483733751
- Combined Prediction Score: 0.6485051718906107
- Mean Citation Score: 235.31811800000003
- Max Citation Score: 239.70432
- Similarity Product: 159.37033097717284

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test